InsiderTrades.com logo
The A.I. story nobody is telling you (Read ASAP)
From TradeSmith   |   Ad
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
Click here to see Louis' new video for yourself.
Robin Wright net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Robin Wright Biography and Net Worth

Director of Vaccitech
Robin Wright has extensive senior level experience as a CFO of public companies in both the pharmaceutical and biotechnology industries. He is a qualified accountant and most recently served as Chief Financial Officer of the biopharmaceutical company Pharming Group NV in the Netherlands.

Robin joined Pharming from Sweden-based Karolinska Development AB (publ.) (KDEV: SS), where he was CFO and Head of Business Development. Mr. Wright was CFO and Head of Business Development at Orexo AB (publ.) (ORX: SS) in Sweden prior to this. Before going to Sweden, he worked in private equity and corporate finance advisory roles, including long periods at Citibank Salomon Smith Barney and Barclays de Zoete Wedd. Mr. Wright holds a BA degree in Chemistry from Oxford University and is a Fellow of the Institute of Chartered Accountants in England and Wales in the UK.

What is Robin Wright's net worth?

The estimated net worth of Robin Wright is at least $125,465.60 as of May 25th, 2023. Mr. Wright owns 48,256 shares of Vaccitech stock worth more than $125,466 as of April 17th. This net worth evaluation does not reflect any other assets that Mr. Wright may own. Learn More about Robin Wright's net worth.

How do I contact Robin Wright?

The corporate mailing address for Mr. Wright and other Vaccitech executives is THE SCHRODINGER BUILDING HEATLEY ROAD THE OXFORD SCIENCE PARK, OXFORD X0, OX4 4GE. Vaccitech can also be reached via phone at 44-18-6581-8808 and via email at [email protected].. Learn More on Robin Wright's contact information.

Has Robin Wright been buying or selling shares of Vaccitech?

Robin Wright has not been actively trading shares of Vaccitech during the last ninety days. Most recently, on Thursday, May 25th, Robin Wright bought 13,750 shares of Vaccitech stock. The stock was acquired at an average cost of $2.66 per share, with a total value of $36,575.00. Following the completion of the transaction, the director now directly owns 48,256 shares of the company's stock, valued at $128,360.96. Learn More on Robin Wright's trading history.

Who are Vaccitech's active insiders?

Vaccitech's insider roster includes Karen Dawes (Director), Christopher Ellis (COO), Graham Griffiths (Insider), and Robin Wright (Director). Learn More on Vaccitech's active insiders.

Are insiders buying or selling shares of Vaccitech?

During the last year, Vaccitech insiders bought shares 2 times. They purchased a total of 23,750 shares worth more than $60,975.00. The most recent insider tranaction occured on June, 26th when Director Joseph Scheeren bought 10,000 shares worth more than $24,400.00. Insiders at Vaccitech own 6.0% of the company. Learn More about insider trades at Vaccitech.

Information on this page was last updated on 6/26/2023.

Robin Wright Insider Trading History at Vaccitech

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/25/2023Buy13,750$2.66$36,575.0048,256View SEC Filing Icon  
12/22/2021Buy10,000$9.97$99,700.00View SEC Filing Icon  
See Full Table

Robin Wright Buying and Selling Activity at Vaccitech

This chart shows Robin Wright's buying and selling at Vaccitech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vaccitech Company Overview

Vaccitech logo
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
Read More

Today's Range

Now: $2.60
Low: $2.59
High: $2.67

50 Day Range

MA: $2.75
Low: $2.33
High: $5.00

2 Week Range

Now: $2.60
Low: $1.64
High: $5.10

Volume

6,497 shs

Average Volume

244,643 shs

Market Capitalization

$100.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
The A.I. story nobody is telling you (Read ASAP)
From TradeSmith   |   Ad
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
Click here to see Louis' new video for yourself.